Adverse reactions to Japanese encephalitis vaccine in travellers

• Published in: The Journal of infection Vol. 32; no. 2; pp. 119 - 122
• Main Authors: Nothdurft, H.D., Jelinek, T., Marschang, A., Maiwald, H., Kapaun, A., Löscher, T.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01-03-1996; Elsevier
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Child; Child, Preschool; Encephalitis Viruses, Japanese - immunology; Female; Human viral diseases; Humans; Infectious diseases; Japanese encephalitis virus; Male; Medical sciences; Middle Aged; Travel; Vaccination - adverse effects; Viral diseases; Viral diseases of the nervous system; Viral Vaccines - adverse effects; Human; Nervous system diseases; Toxicity; Vaccination; Vaccine; Cerebral disorder; Incidence; Infection; Prevention; Immunoprophylaxis; Symptomatology; Viral disease; Arbovirus disease; Central nervous system disease; Japanese encephalitis
• ISSN: 0163-4453; 1532-2742
• DOI: 10.1016/S0163-4453(96)91281-5

Vaccination against Japanese Encephalitis (JE) has been carried out extensively in many Asian countries for the past 20 years. The vaccine was generally considered to be effective and of low reactogenity. However, since 1989 an unusual number of systemic reactions characterized mainly by generalized urticaria and/or angioedema following JE vaccination were reported from Australia, Canada and Denmark. 860 travellers were recruited during a period of 16 months for a prospective study with the aim to investigate the type and incidence of side effects following JE vaccination (JEV) in German travellers. 826 received a primary immunization (2 injections at days 0 and 7–14) and 34 received a single booster injection. A detailed standardized questionnaire was distributed to all vaccines after the first injection. A total of 509 questionnaires could be evaluated, which represents a return rate of 59.2%. 46% of the vaccinees reported about no adverse events at all. 54% reported about one or more adverse effects. Local reactions at the injection site were observed by 209 vaccinees, while 65 reported about systemic side effects like headache, fever, dizziness and generalized rash. There was no significant difference following first or second injection of the primary immunization or the booster injection, respectively, regarding incidence, severity or type of side effects. 2.2% of the vaccinees reporting reactions sought medical advice and 1.8% were judged unfit for work for an average of 2.2 days. The amount of systemic reactions might indicate a potential hazard of serious anaphylactic reactions. Unlike hepatitis A, Japanese encephalitis is an extremely rare disease in travellers. Therefore, the risk of acquiring the disease when travelling to affected areas without prior immunization should be considered against the risk of developing serious side effects after vaccination. We conclude that JEV should remain restricted to travellers with an increased risk of acquiring JE.